Type 1 Diabetes - Renton WA (Metro Seattle)

Summary:

Open label study exploring tolerance of study medication and efficacy of sustaining or increasing c-peptide production in participants with T1DM (type 1 diabetes) diagnosed within the last 0-20 years. Type 1 Diabetes is a result of autoimmune destruction of the insulin producing pancreatic cells resulting in a gradual loss of insulin production. C peptide levels are highly correlated with insulin levels. This study has two options to participate.

1. 4-week participation with 4 on site visits. Will receive study medication. Must be diagnosed with T1D in last 10-20 years.

2. 1 year participation with 9 visits. Chance of receiving placebo or study medication. Diagnosed with T1D in last 0-10 years.

Qualified Participants Must:

• Be diagnosed with Type 1 Diabetes within the last 0-20 years
• Willing to wear a continuous glucose monitor provided by the study
• Be between the ages of 18 to 50

Qualified Participants May Receive:

Compensation up to $1,025

Access to endocrinologist and trained study staff

All study supplies and testing 

No insurance required